Tag Archives: myelofibrosis

August, 2018

22 August
Sierra Oncology Acquires Gilead’s Momelotinib, an Investigational JAK 1/2 and AACVR1 Inhibitor for Myelofibrosis

VANCOUVER, Aug. 22, 2018 /PRNewswire/ – Sierra Oncology, Inc. (Nasdaq : SRRA ), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced it has acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib …
Share

18 July
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with the FDA

SEATTLE, July 18, 2018 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback, the Company plans to conduct a randomized …
Share

8 January
Celgene to Acquire Impact Biomedicines, Adding Novel Therapies for Hematological Malignancies

SUMMIT, N.J. & SAN DIEGO–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up …
Share

6 January
FDA Removes Full Clinical Hold On CTI BioPharma’s Pacritinib for Myelofibrosis

SEATTLE, Jan. 5, 2017 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. …
Share

29 August
CTI BioPharma’s Late-Stage Study of Lead Candidate Shows Mixed Results in Advanced Myelofibrosis

SEATTLE, Aug. 29, 2016 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for the treatment of patients with myelofibrosis …
Share

10 February
CTI Biopharma’s Myelofibrosis Study Placed on Full Clinical Hold, Following Patient Deaths

SEATTLE, Feb. 9, 2016 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the Company’s Investigational New Drug (“IND”) application for pacritinib. Following the issuance of the Company’s February 8, 2016, press release describing the partial clinical …
Share

9 March
CTI BioPharma and Baxter’s Myelofibrosis Drug Meets Primary Endpoint in Late-Stage Trial

Baxter International and CTI BioPharma Corp. announced that its experimental blood cancer drug met its primary endpoint in a late-stage study. The companies announced top-line results for the primary endpoint from PERSIST-1, a Phase III registration clinical trial evaluating pacritinib, an oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients …
Share